Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
NCT00139698
Last updated date
ABOUT THIS STUDY
Efficacy, tolerability and safety of olmesartan alone or in combination with
hydrochlorothiazide in the treatment of mild to moderate essential hypertension
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Essential Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Subject has mild to moderate hypertension
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- History of secondary hypertension
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Essential HypertensionOlmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
NCT00139698
- Medellin, Antioquia
- Barranquilla, Atlantico
- Cartagena, Atlantico
- Bogota, Cundinamarca
- Cali, Valle Del Cauca
- Escobedo, Guayas
- Quito, Pichincha
- NT,
- Shatin, NT,
- Jakarta,
- Jakarta,
- Jakarta,
- Surabaya,
- Seremban, Negeri Sembilan
- Kuching, Sarawak
- San Juan, Metro Manila
- Quezon,
- Singapore,
- Singapore,
- Guei-Shan Shiang, Tau-Yuan Shian
- Kaohsiung,
- Taipei,
- Taipei,
- Khet Rajathevee, Bangkok
- Bangkok,
- Bangkok,
- Chiang Mai,
- Bornova/Izmir,
- Haseki/Istanbul,
- Sihhiye/Ankara,
- S¿hhiye/Ankara,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension | |||
| Official Title ICMJE | A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension | |||
| Brief Summary | Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Essential Hypertension | |||
| Intervention ICMJE | Drug: olmesartan alone or in combination with hydrochlorothiazide | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Enrollment ICMJE | 410 | |||
| Original Enrollment ICMJE | Same as current | |||
| Study Completion Date ICMJE | July 2006 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Colombia, Ecuador, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Turkey | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00139698 | |||
| Other Study ID Numbers ICMJE | A0021002 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | December 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||